We review recent progress in polymer-drug conjugate for cancer nanomedicine. Polymer-drug conjugates, including the nanoparticle prepared from these conjugates, are designed to release drug in tumor tissues or cells in order to improve drugs' therapeutic efficacy. We summarize general design principles for the polymer-drug conjugate, including the synthetic strategies, the design of the chemical linkers between the drug and polymer in the conjugate, and the in vivo drug delivery barriers for polymer-drug conjugates. Several new strategies, such as the synthesis of polymerdrug conjugates and supramolecular-drug conjugates, the use of stimulus-responsive delivery, and triggering the change of the nanoparticle physiochemical properties to over delivery barriers, are also highlighted.
| I N T R O D U C T I O N
In this review we feature various polymer-drug conjugates (PDCs) based nanoparticles (NPs) used to deliver chemotherapeutics. Most of them are designed and fabricated to release drugs in tumor tissues or cells upon the triggering by different stimuli, in order to lower parent drugs' systemic toxicities and improve their therapeutic efficacies. 1 We illustrate some important lessons gleaned from over 60-year development of PDCs, and discuss the promise and outstanding challenges facing the development of PDCs from a perspective of chemistry and materials engineering.
| Polymeric nanomedicine for cancer therapy
Nanomedicine refers to the application of nanotechnology for the prognosis, diagnosis, prevention, and treatment of clinical conditions. 2 Nanomedicine can enhance therapeutics and diagnostics in many ways, as has been reviewed. [3] [4] [5] [6] [7] [8] [9] In cancer chemotherapy the NP enables the preferential delivery of drugs to tumors owing to the enhanced permeability and retention (EPR) effect-NPs are preferentially taken up by the leakier vasculature in tumor beds than small molecules and are retained because of the tortuous lymphatics. [10] [11] [12] Several nanoparticulate therapeutics, for example, Doxil TM ($100 nm PEGylated liposome loaded with doxorubicin) 13 , Abraxane TM ($130 nm paclitaxel albuminstabilized NPs) 14, 15 and Onivyde TM (nanoliposome loaded with irinotecan), 16 have been approved for use by the FDA, and have shown improved pharmacokinetics and reduced adverse effects compared to their parent drugs. Polymeric drug delivery NPs, one of the major delivery platforms, has actively evolved its paradigm from water-soluble polymeric carriers, to liposome, micelle, dendrimer, polymersome, and other polymeric nanostructures.
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| The development of the PDC
PDC is one of the most important and oldest polymeric delivery systems ( Figure 1 ). The conjugation of drugs to macromolecules was initiated about sixty years ago. 20 Early work in 1950-1960s focused on numerous water-soluble PDCs, especially poly(vinylpyrrolidone) conjugates. 21 Math e et al. pioneered conjugation of drugs to immunoglobulins in 1958, setting the stage for PDCs. 22 In 1975 Ringsdorf presented a clear concept of the use of polymers as targetable drug carriers, 23 which motivates rational design of the first generation of polymer therapeutics candidates (and firstgeneration PDCs) that later entered clinical testing. 24 Meanwhile
Davies and coworkers modified proteins with poly(ethylene glycol) (PEG) to improve protein's circulation half-life, immunogenicity, PEG-L-asparaginase, for treating leukemia), and will not be discussed in this review. 26, 27 The important first generation PDCs include: poly(N-hydroxypropyl methacrylamide) (polyHPMA), which is synthesized by Ulbrich and Kopeček, and later co-developed with Duncan [28] [29] [30] [31] [32] [33] ; poly(glutamic acid) with paclitaxel (Xyotax TM or Opaxio TM ) or camptothecin (CT-2106) conjugates by Li and Wallace [34] [35] [36] ; poly(styrene-maleic anhydride)-neocarzinostatin conjugate (SMANCS, Zinostatin Stimalmer TM ) by Maeda, which is approved in Japan for the treatment of hepatocellular carcinoma. 37, 38 In the late 1980s and early 1990s nanoparticulate drug delivery systems, including PEGylated polymeric micelles and liposomes, were rapidly developed after the discovery of EPR effect. Figure 2 ).
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| Stimuli-sensitive PDC
Although it is suggested that the EPR effect exist in human tumors, 46, 47 it is still questionable whether the EPR effect is sufficient to significantly improve the survival of cancer patients by nanomedicine. 48, 49 Several delivery barriers limit the transport of NPs deep into 
| Polymer
Polymers that have functional groups for the incorporation and release of drugs in PDCs must be well characterized ( Figure 1a ). All in vivo metabolic products of PDCs should be nontoxic and nonantigenic.
Polymers in PDCs should be either biodegradable or completely eliminated from the body. In this review, various polymers are discussed, including: hydrophilic polymers used in first-generation PDCs for clinical trials, such as polyHPMA, and PEG 1, [56] [57] [58] [59] ; copolymers, especially block copolymers that can be formulate to nanostructures such as micelle 60 or polymersome 61, 62 ; dendrimers 63 and hyperbranched polymers, 64, 65 and natural macromolecules such as polysaccharides (dextran, cellulose, chitosan) and polypeptides. The half-life of polyHPMA-Doxo conjugate (molecular weight 1230 kDa) in blood was up to 28 times longer, and the elimination rate from the tumor was 25 times slower than that of free Doxo. 
| Block copolymer's composition
The relative ratio of the hydrophobic to hydrophilic block length profoundly affects the NP's morphology. [81] [82] [83] Typically the morphology of prepared amphiphilic block copolymer NP is spherical, particularly if the molecular weight of the hydrophilic block exceeds that of the hydrophobic block (so-called star micelles). However, if the copolymer is asymmetric in its relative block lengths (i.e., the hydrophobic block is considerably longer than the hydrophilic block) during the selfassembly process, varying morphologies can be obtained. 84, 85 In addition, the copolymer's concentration in water-miscible solvent affects the final NPs' size. 86 The use of triblock polymers could improve the NP's stability. 54 Nevertheless, there lacks systemic studies on the block copolymer ratio or composition on the in vivo circulation and stability of the NPs' morphology, presumably due to the technical difficulty to monitor the sub-100 nm polymeric NPs in vivo. Recent in vivo pharmacokinetic studies using dual-radiolabeling of lipid and drug in liposomes could provide a valuable example for the study the biodistribution of copolymer-based PDCs in vivo. 87 Notably, recent studies have shown that the zwitterionic copolymers (i.e., polymers containing both cationic and anionic groups) are super-hydrophilic, which can prolong the circulation of NPs in the way similar to PEG. 88 
| Synthetic strategy of PDC
There are three strategies for drug-polymer conjugates ( Figure 3 ).
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The first is conjugating a drug to a pre-synthesized polymer, named as "conjugation to." The second is to conjugate a drug to a monomer prior to polymerization, namely "conjugation through." The last is the polymerization of drugs to prepare PDCs, where drugs are directly used in the polymerization as monomers or initiator. 90 The last two strategies have been recently developed to prepare PDCs, aiming to overcome the non-controlled drug conjugation problem in the "conjugation to"
strategy (see Sections 3.1 and 3.2).
| Drug release and the conjugation linker
An ideal PDC for cancer treatment should be able to release the drug in tumor tissues or cells, but not to the normal tissues or cells. Two types of linker can be positioned between drug and polymer: cleavable linker and non-cleavable linker. Non-cleavable linkers, such as thioether linkers, have been seen in the antibody-drug conjugates (ADCs). 91 The release of the drug from these ADCs requires complete hydrolysis of the polypeptide backbone of the antibody in cell lysosomes. 92 One example is T-DM1 (Kadcyla   TM   ) , an ADC to treat metastatic breast cancer, which has the thioether linker, and exhibited better antitumor efficacy than the same ADC but with disulfide linker. 93 However, the use of non-cleavable linker of degrading the delivery platform after cell uptake might not be feasible in more complex NP systems.
Enormous synthetic efforts have been devoted to design stimulussensitive cleavable linkers to trigger drug release (Figure 4 ). During the NP's extravasation, local tumor microenvironmental factors, such as pH (6.7-7.0), 94 redox state (hypoxic tumor microenvironment 95 and elevated reactive oxygen species generated by tumor cells 96 ) and specific molecules overexpressed in tumor (e.g., matrix metalloproteinases
[MMP]), 97 can be utilized to disrupt PDCs' structures to release loaded drugs, or induce NPs size or morphology change for enhanced penetration (see Section 3.5). Besides the endogenous stimuli, the external stimuli-such as magnetic field, temperature, light, and ultrasound-can be applied in a spatiotemporal manner to control drug release. 
| Redox sensitive linker
The difference in redox potential between normal and tumor tissues, and between the intracellular and extracellular environment, can be exploited for triggered drug delivery. 115 In the nanomedicine field, it is generally believed that the concentration of glutathione, a reducing tripeptide with thiol group, in cancer cells is 100-to 1,000-fold higher than in the blood, and in a tumor mass the glutathione concentration is also markedly (100-fold) higher than the extracellular level of glutathione in normal tissue. 116 However, studies showed that in mice model a total fourfold higher level of glutathione in tumor tissues compared with normal tissues, and there exists significant heterogeneity of redox status in the tumor tissue. 117 In human cancer patients, glutathione levels tend to be elevated in breast, ovarian, head and neck, and lung cancers compared with disease-free peritumoral or healthy tissue; conversely, brain and liver tumors patients exhibit lower tissue level of glutathione in tumor compared with that in healthy tissue. 118 In addition, two studies concluded that glutathione levels did not differ between parenchymal tissue sampled from healthy patients and uninvolved parenchymal tissue from lungs with tumors. 119, 120 Therefore, right preclinical models and tumor types have to be rationally chosen when applying redox-sensitive PDCs.
The reducing materials in vivo could facilitate the cleavage of redox-sensitive bonds such as disulfide bond and diselenide bond. 121 For example Kopeček and coworkers conjugated the photosensitizer mesochlorin e6 to HPMA copolymer via a disulfide bond, which showed a time-dependent release of Mce6 and concomitant increase in the photodynamic efficacy when exposing to DTT. 122 However, the disulfide-based linker showed relatively short in vivo stability less than
Three synthetic strategies of polymer-drug conjugates 1 day in ADCs, respectively, which is much shorter than the parent antibody moieties. 108 The in vivo circulation stability PDCs containing redox-sensitive linker should be evaluated carefully in future.
| Enzyme sensitive linker
The increased expression of certain local enzymes in cancer, such as MMP, not only can be regarded as a biomarker for disease diagnosis and prognosis, but also represents a means for enzyme-triggered drug release in tumor. [123] [124] [125] [126] Early studies on detailed degradation studies of oligopeptide sequences attached to polyHPMA-based PDCs identified the short peptide GFLG, specific for cathepsin B. 127 The poly-HPMA PDCs with such linker have shown efficacy in various preclinical efficacy study and have entered the clinical trials. 128, 129 Another widely used short peptide linker is citrulline-valine, which can be cleaved by specific lysosomal proteases but impart greater stability in plasma. Of note Brentuximab vedotin (Adcetris TM approved for the use in Hodgkin lymphoma) is an ADC containing such dipeptide linker to facilitate release of the drug, monomethylauristatin E. 130 Other short peptides linkers include PVGLIG (cleaved by MMP-2/MMP-9), 131 and SSKYQL (cleaved by prostate-specific antigen). 132 One can envision that the presence of certain enzymes as biomarkers potentially could be utilized to design a PDC for personalized medicine, once the concentration of enzymes at the tumor site should also be sufficient for the disruption of the PDC.
| Light sensitive linker
There has recently been growing interest in light-responsive NPs for triggered drug delivery. The use of an optical stimulus is appealing because it could provide a greater selectivity in terms of control over the moment and the location of drug release, and potentially transfer photonic energy to heat, acoustic wave, or induce reactive species such as singlet oxygen in photodynamic therapy. 133 In terms of light- was developed based on the C4'-dialkylamine-substituted heptamethine cyanine linker and has been used in a light-triggerable ADC; upon the irradiation, the photo-oxidation of the cyanine polyene could generate a secondary amine and promote the cleavage of the carbamate bond to release the drug (Figure 4) . 142, 143 The use of inorganic NPs such as gold NPs or upconversion NPs for triggered drug release offers another intriguing strategy and has been reviewed elsewhere.
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| In vivo drug delivery barriers for PDCs
| Circulation
To achieve therapeutic efficacy, NPs must first overcome systemic barriers with prolong circulation time, especially clearance by mononuclear phagocytic system (or so-called reticuloendothelial system), hepatobiliary system and urinary system. 147 In general, NPs with sizes below 100 nm are suitable for systemic (usually intravenous) distribution, as larger ones cause embolic phenomena 148 ; while there seems no significant difference in circulation half-life for various sized NPs in the range of 30-100 nm. 149 To avoid rapid clearance by the kidneys, the NP's hydrodynamic size should be larger than 6 nm. 150 Notably, most HPMA PDCs in clinical trials have NPs size below 10 nm (Table 1) or moderate molecular weight (less than 40 kDa, Table 1 ), which may affect their in vivo circulation and accumulation profiles. The NP should keep its size in circulation and not be destabilized under flow or at physiological temperature. 151 In addition, the NP should not bind with proteins in blood that could lead to aggregation, or be uptaken by the macrophages in the mononuclear phagocytic system, all of which can lower the dose of NPs reaching tumors. 152 Coating of NPs with PEG that mimics a cell's glococalyx, [153] [154] [155] known as "PEGylation," can suppress protein absorption to NPs and delay the rate of NP uptake and clearance, greatly prolonging circulation time. 156 The NP's circulation half-life is impacted by the extent of PEGylation on NPs surface, 157, 158 and may be reduced upon repetitive administration, which has been reviewed elsewhere. NPs extravasate into tumor tissues. 162 In general, current consensus is that sub-100 nm may be the optimal NP size range for passive tumor targeting, which may vary depending on individual NP's composition and formulation. Besides, the NP surface charge (see discussion in Section 3.5.2) and the aspect ratio of NPs can affect NP's, in vivo circulation time and tumor penetration capability 163 and NP's cell uptake. 164 Other strategies of improving NP's tumor penetration include coinjecting drugs to reduce tumor's extracellular matrix density, 165, 166 and conjugating tumor-homing or tumor penetration ligands.
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| Tumor cell uptake
After reaching the tumor cells, NPs may need to cross the barrier of the cell membrane to deliver the loaded drugs into specific organelles to achieve efficacy. For hydrophilic polymer based PDCs, it is found that some PDCs, such as polypeptides 182 or dextran, 183 cannot be naturally degraded into small fragments that can cross the lysosomal membrane; the accumulated polymers in the lysosome increase the osmotic pressure and adversely affect the biocompatibility. 184 Another study shows that most polyHPMA-based PDCs quickly and evenly diffuse throughout the cytoplasm and remain excluded from membrane-bound organelles;
only strongly cationic HPMA copolymers can bound to microtubules; the nuclear entry kinetics were affected by the ratio of the HPMA to comonomer compositions. 185 
| N E W ST R AT E G I E S I N P DC
The purpose of this section is to highlight some novel ways in which chemistry and nanotechnology are being applied to tackle challenges in PDC development.
| "Conjugation through" PDC
The "conjugation through" method in PDCs requires monomer-drug conjugates not interfere the polymerization. 89 The "conjugation through" method could address the drawbacks in the "conjugation to" strategy, such as inconsistent and uncontrolled site conjugation along the polymer backbone. 89 The drug loading can be controlled by adjusting the feed ratio of monomer-drug conjugates; and the drug release can be controlled by the judicious selection of the linker between the drug and the monomer, which could be stimulus-responsive ( Figure   3b ). 186 Such method thus allows for even higher drug-loadings than the "conjugation to" approach, by avoiding steric hindrance and accessibility limitation during the conjugation.
A few of monomer-drug conjugates have been synthesized to prepare PDCs and corresponding NPs. Ring-opening metathesis polymerization (ROMP) is often unitized in the "conjugation through" strategy.
Examples include the norbornene-Doxo conjugate with the acidsensitive carbamate linker, 187 or the similar norbornene-Doxo conjugate with the hydrazone linker. 188 Multiple drugs including Doxo, Cpt, and cisplatin were individually tethered to the norbornene monomer with different stimulus-responsive linkers; upon ROMP, precise ratio of drugs were controlled linked to the polymer, and resulted NPs could orthogonally triggered release individual drugs. 189, 190 Similarly, the reversible addition fragmentation transfer (RAFT) polymerization is reported for "conjugation through" method; for example, Cpt-tethered acrylate with redox-sensitive disulfide linker was polymerized by RAFT to formulate redox-sensitive NPs. 191 However, PDCs synthesized by the ROMP or RAFT had non-biodegradable polymer backbones, which limits their potential clinical application. 186 Alternatively, the ringopening polymerization (ROP) is applied in "conjugation through"
method. For instance, a campothecin-tethered cyclic carbonate monomer was prepared with the disulfide linker between the drug and carbonate. The ROP of such drug-carbonate conjugates resulted in a biodegradable polycarbonate PDC which can be further formulated to redox-responsive NPs. 186 
| Polymerizable drug
The use of drug as the monomer could significantly increase the drug loading. However, not many drug molecules fit for such strategy.
Often, drug molecules contain two functional groups that allow for polycondensation reaction. Another drawback lies in the polymerization chemistry especially in polycondensation reaction. Such polymerization cannot produce high molecular-weight polymer (e.g., over 10 kDa) and lacks polydispersity control. In addition, the introduction of stimulusresponsive group is not straightforward. Early work to prepare PDCs via such strategy often focus on the polyanhydrides which degrades through hydrolysis in vivo without burst release. Drugs such as ibuprofen, naproxen, 192 ferulic acid, 193 or morphine 194 have been used as monomer in the polymerization.
Recently a new facile strategy has been reported to use the stimulus responsive group to induce further depolymerization in the PDCs using drugs as monomers. 10-hydroxycamptothecin, a diol drug, was polymerized with o-nitrobenzyl, a photosensitive group, caged 2,6-bis (hydroxymethyl)aniline via condensation polymerization. The resulted polycarbonate PDCs could be responsive to the UV-light triggering: the o-nitrobenzyl group was detached from the polymer and unfolded the aniline groups, which could successively trigger the depolymerization via the 1,4-elimination reaction ( Figure 5 ) and released the drug.
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Similar 10-hydroxycamptothecin-loaded polycarbonate caged with redox disulfide linker was also reported. light, 197 and then photosensitizers generate cytotoxic oxygen species (either singlet oxygen or oxygen radicals). 198 Most photosensitizers bind to normal cells as well as to cancer cells, leading to unwanted offtarget activation from environmental (ambient) light. [199] [200] [201] [202] The conjugation of photosensitizer to polymeric delivery vehicles is designed to improve photosensitizer's performance by increasing specificity and/or uptake in tumors, or decreasing phototoxicity to normal tissue. 203, 204 Early photosensitizer-drug conjugates include polyHPMA, PEG and antibody conjugates. [205] [206] [207] [208] Factors such as the charge and hydrodynamic size of the conjugates affect the cellular uptake rate and tumor accumulation of hydrophilic polymer-photosensitizer conjugates. 209, 210 In many cases the covalent linkage between photosensitizer and polymer significantly reduced the quantum yield. 211 The enzymaticcleavable linker, or environmental-sensitive linker, was introduced to enhance both the selectivity of photosensitizer and the quantum yield; An alternative delivery approach was proposed to use relatively larger NPs with initial size (still sub-100 nm NPs), but once docking at tumor sites, NPs were switchable to small particles to facilitate tumor penetration. 233 The stimuli-responsive NPs that are able to shrink their sizes by responding to enzymes or light exhibited the enhanced tumor penetration of NPs and improved efficacy. 234, 235 Recently, a new pH sensitive NP was prepared by poly(caprolactone)-co-poly(amidoamine)
-platinum prodrug conjugate with a pH sensitive cis-aconityl linker (degrade $pH 6.8) between poly(amidoamine) and poly(caprolactone) (Figure 7a ). The initial 100 nm sized NPs degrade in acidic tumor interstitial spaces to 5-nm poly(amidoamine)-drug conjugates with enhanced diffusion capability.
| Surface charge
Positively charged NPs often have short circulation half-life compared with PEGylated or anionic NPs. [236] [237] [238] [239] However cationic NPs may penetrate tumors deeper than neutral or anionic NPs due to the attractive electrostatic forces between cationic NPs and anionic endothelial glycocalyx. 240 Positively charged NPs also generally have better cellular uptake than negatively ones. 241, 242 A pH-sensitive PDC-based NP was designed to achieve multi-stage charge changing to improve delivery efficiency: NP's surface charge maintained slightly anionic at pH 7.4; in tumor tissues with pH $ 6.8, the pH-sensitive cis-aconityl group was cleaved from the surface and expose the positive amine groups, which It is known that amphiphlic or lipid-like molecules could potentially self-assemble into supramolecular nanostructures. 247 Taking advantages of the self-assembly properties of these small molecules, an amphiphilic prodrug conjugate was synthesized by conjugating two hydrophobic Cpt molecules to a short oligo(ethylene glycol) as the hydrophilic segment via a biodegradable b-thioester bond. Such amphiphilic prodrug conjugates have high drug loading and form stable 100 nm nanoliposome (Figure 8a ). 248 Similar approach was applied to synthesize amphiphilic PEG-block-dendritic polylysine-CPT conjugate that could assemble to nanorod. 249 Another reported strategy is to conjugate hydrophobic squalene to hydrophilic drugs or prodrugs to construct NPs. 250 Doxo, gemcitabine and other drugs were "squalenoylated" and formulated into $100-150 nm sized NPs ( Figure   8b ). 251 An extreme strategy is recently reported to synthesize an amphiphilic drug-drug conjugate by directly connecting the hydrophilic anticancer drug irinotecan to the hydrophobic anticancer drug chlorambucil via a hydrolyzable ester linker, which can be assembled to NPs with $80 nm size (Figure 8c ). 252 Similar conjugate was synthesized between the hydrophilic drug floxuridine with the hydrophobic drug bendamustine. 253 Besides amphiphilic molecules or lipids, another interesting molecule to prepare prodrug conjugates is the small peptide. It is known that small peptides can assemble into filamentous supramolecular structures. 254 Such peptide-drugs conjugates have been intensively studied to formulate hydrogel system, and are reviewed elsewhere. 250, [255] [256] [257] [258] A recent study demonstrate that a rationally designed peptide-Cpt conjugate be formulated to nanostructures for drug delivery. A b-sheet-forming peptide sequence derived from the tau protein was conjugated to Cpt via a redox-sensitive disulfylbutyrate linker, and the resulting nanostructures could vary from long filaments to short filaments and then to nanotubes with high drug loadings (Figure 8d ). [259] [260] [261] Studies also showed the choice of the degradable linker between the peptide and Cpt affect the nanostructure. The carbonate linker is more preferred than ester since it minimizes the potential aggregation in cell culture, which could compromise Cpt's potency. 262 
| O U T L O O K
The routine clinical use of PEGylated proteins since 1990s and the recent large investments in ADCs overshadow the development of PDCs. Although so many interesting designs and impressive data presented in this review, there seems a long and arduous journey to bring more PDCs or NPs into clinical practice. 129, 263 Several recent publications try to provide their solutions for the whole nanomedicine field. [264] [265] [266] Progress in the field will depend on a fundamental understanding of chemistry, materials science, biology, and clinical practice to allow rational design of optimized NPs of PDCs, tools for delivering them and measure outcomes. In terms of chemistry design, one has to bear in mind the clinical application and whole-organism pharmacokinetics. One example is the in vivo studies in ADCs revealed an in vitro stable linker may have unexpected instability in vivo and cause reduced efficacy. 267, 268 Many of the first generation PDCs were developed before the concept of nanomedicine and the study of the relationship between NPs' sizes and their in vivo circulation and intratumoral accumulation; thus such PDCs have moderate molecular weight and small particle sizes (Table 1) , which may result in some of the failure in clinical trials. In addition, there lack standard or optimized preclinical or clinical protocols to evaluate PDCs' stability, tumor penetration, metabolism, and toxicity. 269 The development of labeling/imaging technique and nano-device system may help monitor the in vivo use of PDCs. Of all note that many data obtained in animal models cannot be
Four representative supramolecular drug conjugates that can assemble into nanoparticle for drug delivery easily translated into humans; in the frequent-used subcutaneous tumor xenografts the access of the blood to the tumor interstitium is greater than that in solid tumors in patients. 270, 271 Furthermore, the advances in cancer biology can change the landscape of the field rapidly, as seen in the recent promising therapeutics in cancer immunology. 272, 273 Last but not least, nontrivial optimization and engineering has a bearing on the eventual translation of NPs from preclinical experimental models to daily clinical practice. 274 The PDC and NP preparation should not require complex multistep processes; the scalability of NPs should not represent a problem in industry; the NP product should be sufficiently stable under storage and easy to use in clinics, that is, no complex administration protocols or regimens. 172, 275 All of these prudent considerations will ensure that the field of PDC-based NPs reaches its full potential for clinical impact in cancer therapy.
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